LiquidGx™ NGS

[17 genes]

LIQUID BIOPSY FOR NON-INVASIVE CANCER TESTING

A molecular test alternative for when tissue-based biopsy is not available or is insufficient

Designed for precision treatment and drug resistance monitoring

- Quantitatively detect cancer-driving variants and drug resistant markers before making treatment decisions
- Find actionable results even after tissue samples have been exhausted
- Requires two 10ml tubes of blood that can easily be worked into patient workflow
- Detects single nucleotide variants (SNVs), gene fusions, insertion and deletions (Indels), copy number variations (CNVs), and microsatellite instability (MSI) status
- Input includes both ctDNA and ctRNA allowing for optimal fusion detection

AKT1	ALK**	BRAF	EGFR	ERBB2	HRAS
KIT	KRAS	MAP2K1	MET**	NRAS	PDGFRA
PIK3CA	PTEN	RET*	ROS1*	TP53	

- Next Generation Sequencing test, coverage of >170 variants in 17 genes frequently mutated in cancer
- Includes MSI for selection of anti-PD1 therapy
- Ability to detect novel fusions lowers the rate of false negatives

	SNVs	Indels	Fusions	CNVs	MSI
Limit of detection	**0.1%** (as low as 0.02%)	**0.1%** (as low as 0.01%)	**0.1%** (as low as 0.01%)	**0.5 extra copies** (as low as 0.2 copies)	**2%**

Relevant Solid Tumor Therapies

- Afatinib (Gilotrif®)
- Alectinib (Alecensa®)
- Bevacizumab (Avastin®)
- Brigatinib (Alunbrig®)
- Cabozantinib (Cometriq®)
- Ceritinib (Zykadia®)
- Cetuximab (Erbitux®)
- Crizotinib (Xalkori®)
- Dabrafenib (Tafinlar®)
- Erlotinib (Tarceva®)
- Everolimus (Afinitor®)
- Gefitinib (Iressa®)
- Imatinib (Gleevec®)
- Nilotinib (Tasigna®)
- Nivolumab (Opdivo®)
- Osimertinib (Tagrisso®)
- Panitumumab (Vectibix®)
- Pembrolizumab (Keytruda®)
- Sorafenib (Nexavar®)
- Sunitinib (Sutent®)
- Temsirolimus (Torisel®)
- Trametinib (Mekinist®)
- Trastuzumab (Herceptin®)
- Vandetanib (Caprelsa®)
- Vemurafenib (Zelboraf®)

HELICE
GENOMIC SCIENCES, INC.

helicegenomics.com
info@helicegenomics.com
+632 624 9684 · +63917 865 8743

LiquidGx™ NGS [17 genes]

LIQUID BIOPSY FOR NON-INVASIVE CANCER TESTING

Clear, color-coded recommendations:

- FDA-approved drugs for that indication
- FDA-approved drugs for other indications that may be beneficial
- Drugs that will likely not show any benefit due to the presence of resistance markers
- Easy to read with relevant clinical trial information based on geography (up to 5 trials listed per variant found)

MSI can predict a predisposition to mutations as a result from impaired DNA mismatch repair (MMR) and effective anti-PD-1 therapy

MSI status is determined by detecting the length of mononucleotide repeats at five genomic sites (BAT-25, BAT-26, NR-21, NR-24, and NR-27)



A shift in repeat length (formation of a second peak) observed in the **cell-free DNA (cfDNA)** compared to **genomic DNA (gDNA)** at 3 or more sites indicates MSI-High



T-Cell cannot recognize tumor cell as foreign



With anti-PD1 therapy, T-Cell can now recognize tumor cell as foreign



Quantifiably detects variants, including drug resistant markers

Ideal for longitudinal monitoring

Testing and interpretation performed by Admera Health LLC · 126 Corporate Boulevard, South Plainfield, New Jersey, USA 07080 · LiquidGx™ is a trademark of Admera Health LLC.

HELICE GENOMIC SCIENCES, INC.

helicegenomics.com
info@helicegenomics.com
+632 624 9684 · +63917 865 8743